Niemann–Pick C1 (NPC1)

Niemann–Pick C1 (NPC1) is a large, polytopic 1,278-amino-acid integral cell membrane glycoprotein localized to the limiting membrane of late endosomes and lysosomes in eukaryotic cells. Encoded by the NPC1 gene on human chromosome 18q11.2, NPC1 cooperates with the soluble luminal sterol-binding protein NPC2 to export unesterified cholesterol derived from receptor-mediated endocytosis of low-density lipoprotein (LDL) particles across the glycocalyx-lined lysosomal membrane into the cytosolic compartment and endoplasmic reticulum. Loss-of-function mutations in NPC1 account for approximately 95% of clinical cases of Niemann–Pick disease type C, an autosomal-recessive lysosomal lipid storage and neurodegenerative disorder.

Beyond its physiological house-keeping role in cellular sterol homeostasis, independent genome-wide haploid genetic and small-molecule screens in 2011 identified NPC1 as the obligate intracellular endolysosomal receptor required for cytoplasmic entry by members of the family Filoviridae (including Orthoebolavirus, Bundibugyo ebolavirus, and Orthomarburgvirus). Unlike surface-binding receptors, NPC1 interacts with the proteolytically primed viral envelope glycoprotein (GP₁) exclusively inside acidic late endosomes via its second luminal loop (Domain C), making small-molecule and genetic variations at the NPC1 Domain C interface a primary determinant of vertebrate host range and a target for host-directed antiviral therapeutics.

13-Transmembrane Topology and Luminal Domains (A, C, and I)

High-resolution X-ray crystallography and single-particle cryo-electron microscopy (cryo-EM) structures determined by Xiaochun Li, Nieng Yan, and colleagues show that human NPC1 spans the endolysosomal phospholipid bilayer via 13 transmembrane α-helices (TM1–TM13) and projects three large, heavily N-glycosylated hydrophilic domains into the acidic lysosomal lumen (pH 4.5–5.5):

• Luminal Domain A (N-Terminal Domain, NTD, residues 25–264): Connected to TM1 via a flexible proline-rich linker, the NTD contains a hydrophobic sterol-binding pocket stabilized by nine conserved disulfide bonds. Unlike the soluble NPC2 protein (which binds cholesterol with its isooctyl hydrocarbon tail buried deep in the pocket and its 3β-hydroxyl group exposed), the NPC1 NTD binds cholesterol in the opposite orientation, cradling the 3β-hydroxyl polar headgroup at the base of the cavity.
• Transmembrane Sterol-Sensing Domain (SSD, TM3–TM7, residues 615–797): Shares sequence and structural homology with the sterol-sensing domains of HMG-CoA reductase, SCAP (SREBP cleavage-activating protein), and the Hedgehog receptor Patched-1 (PTCH1), forming a hydrophobic intramembrane tunnel that conducts cholesterol into the outer leaflet of the lysosomal bilayer.
• Luminal Domain C (Middle Luminal Domain, MLD, residues 373–620): Projecting between TM2 and TM3, Domain C folds into an α/β core flanked by two protruding antiparallel β-hairpin loops (Loop 1 and Loop 2) that form the transient docking scaffold for both soluble NPC2 during cholesterol transfer and the cleaved filovirus GP₁ receptor-binding site.
• Luminal Domain I (C-Terminal Luminal Domain, CTD, residues 854–1098): Located between TM8 and TM9, Domain I stabilizes Domain C and completes the ~80 Å luminal tunnel leading toward the transmembrane sterol-sensing channel.

The "Hydrophobic Hand-Off" Model of Lysosomal Sterol Export

When circulating LDL particles bind the cell-surface LDL receptor and enter the endocytic pathway, lysosomal acid lipase (LAL) hydrolyzes cholesteryl esters into free unesterified cholesterol. Because the inner leaflet of the lysosomal limiting membrane is coated by a dense, 8-nm-thick polysaccharide glycocalyx (composed of LAMP-1 and LAMP-2 glycoproteins) that prevents spontaneous sterol diffusion, export proceeds via a two-step hydrophobic hand-off:

1. Soluble luminal NPC2 extracts free cholesterol from internal lysosomal membranes and docks onto Domain C of membrane-embedded NPC1.
2. Docking aligns the hydrophobic pocket of NPC2 directly with the opening of NPC1 Domain A (NTD), allowing cholesterol to slide from NPC2 into the NTD without exposing its insoluble hydrocarbon rings to the aqueous lumen.
3. A conformational pivot between Domain A, Domain C, and Domain I delivers the sterol down the central luminal tunnel into the transmembrane SSD channel across the glycocalyx barrier.

Biallelic loss-of-function mutations in NPC1 (~95% of patients) or NPC2 (~5% of patients) cause Niemann–Pick disease type C (NPC), an autosomal-recessive neurovisceral storage disorder with an estimated incidence of 1 in 100,000 live births. The single most prevalent missense allele in Western European populations is p.Ile1061Thr (I1061T) within luminal Domain I, which destabilizes ER protein folding and targets the nascent polypeptide for endoplasmic-reticulum-associated degradation (ERAD) via the ubiquitin–proteasome system.

When functional NPC1 is absent from late endosomes, unesterified cholesterol, bis(monoacylglycero)phosphate (BMP), sphingomyelin, and gangliosides (GM2 and GM3) accumulate inside enlarged endolysosomal compartments, while the endoplasmic reticulum is starved of sterol feedback—inappropriately activating SREBP-2 transcription of de novo cholesterol biosynthesis and LDL uptake. Clinically, lipid trafficking failure affects Purkinje neurons of the cerebellum and brainstem nuclei, manifesting as vertical supranuclear gaze palsy, progressive cerebellar ataxia, dysarthria, hepatosplenomegaly, and cognitive decline. Disease-modifying pharmacotherapies include the glucosylceramide synthase inhibitor miglustat, the blood-brain-barrier-penetrant amino acid derivative N-acetyl-L-leucine, and cyclodextrin or heat-shock protein (HSP70) proteostasis modulators.

Cathepsin Unmasking and Domain C Loop Recognition

In 2011, Jan Carette, Kartik Chandran, Thijn Brummelkamp, and coworkers (using haploid human cell insertional mutagenesis) and Marceline Côté, James Cunningham, and coworkers (using small-molecule benzylpiperazine adamantane derivative 3.47 screening) independently demonstrated that cells lacking NPC1 are resistant to infection by all tested members of the Filoviridae family. Crucially, viral entry does not require the cholesterol-transporting activity of the transmembrane SSD, but depends specifically on physical docking to luminal Domain C.

After a virion attaches to cell-surface C-type lectins or TIM/TAM phosphatidylserine receptors and is internalized via macropinocytosis into the endocytic pathway, endosomal acidification activates host cysteine proteases cathepsin B and cathepsin L. These proteases cleave away the heavily glycosylated outer glycan cap and mucin-like domain of the trimeric viral envelope glycoprotein (GP_1,2), reducing the 130-kDa GP₁ subunit to a ~19-kDa primed core that exposes a hydrophobic crest and pocket. Co-crystal structures (Wang et al., 2016) reveal that two protruding β-hairpin loops of NPC1 Domain C insert directly into this newly exposed viral trough:

• Loop 1 (residues 420–428) and Loop 2 (residues 498–506, containing aromatic residues Phe503 and Tyr504) insert into the hydrophobic cavity of primed GP₁, displacing a short viral α-helix and triggering the release of the transmembrane GP₂ fusion subunit to drive endosomal membrane fusion.

Evolutionary Polymorphisms and Chiropteran Reservoir Tropism

Because the NPC1 Loop 1 and Loop 2 sequence is highly conserved across mammals, most mammalian species are permissive to filovirus entry at the cellular receptor level. However, comparative evolutionary genetics across bats (Order Chiroptera)—the primary natural reservoirs implicated in zoonotic spillover—has uncovered natural receptor-level resistance polymorphisms. For example, while the Egyptian fruit bat (Rousettus aegyptiacus) and hammer-headed bat (Hypsignathus monstrosus) encode canonical aromatic residues at NPC1 Loop 2 that support efficient entry, African straw-colored fruit bats (Eidolon helvum) carry a single non-synonymous substitution (Asp502Phe in NPC1 Domain C Loop 2) that sterically blocks binding by Orthoebolavirus zairense GP₁ while remaining permissive to other filovirus lineages—illustrating an ongoing host–virus evolutionary arms race at the NPC1 Domain C interface.

Why can Niemann–Pick C1 deficiency protect cells against filovirus entry even if cholesterol transport is restored?

Mutagenesis studies demonstrate that the cholesterol-export function of NPC1 and its viral receptor function are structurally separable. Cells expressing engineered NPC1 variants with mutations in the N-terminal sterol-binding Domain A or the transmembrane sterol-sensing domain (SSD) remain fully susceptible to viral entry as long as luminal Domain C is intact. Conversely, targeted deletions or point mutations in Loop 2 of Domain C (such as Phe503Ala/Tyr504Ala) abolish viral glycoprotein binding without preventing basic membrane insertion.

How does the experimental small molecule U18666A differ from Domain C entry inhibitors?

U18666A is a cationic amphiphilic sterol derivative that binds directly within the transmembrane sterol-sensing domain (SSD) of NPC1, blocking cholesterol efflux and inducing a cellular phenotype that mimics Niemann–Pick type C disease; at high concentrations it indirectly impairs endosomal trafficking and membrane composition. In contrast, peptidomimetics, bispecific antibodies (which tether an endosome-targeting domain to an anti-NPC1 or anti-GP1 core Fab), and adamantane-piperazine compounds such as compound 3.47 specifically compete for the protein–protein interaction between cleaved GP₁ and NPC1 Domain C.

How do bispecific "Trojan horse" antibodies target the NPC1 interaction inside endosomes?

Because the NPC1-binding site on the viral glycoprotein remains hidden underneath the glycan cap until the virus is inside an acidic late endosome, conventional cell-surface monoclonal antibody therapy cannot easily reach the recessed receptor-binding pocket or intracellular NPC1. Researchers have engineered bispecific antibodies that use one arm to hitchhike on the exterior of the intact virion at the cell surface, riding the virus into the endosome via macropinocytosis; once cathepsins cleave off the viral glycan cap inside the endosome, the second antibody arm blocks either the exposed viral receptor-binding site or NPC1 Domain C.

1. Carette, J. E., Raaben, M., Wong, A. C., Herbert, A. S., Obernosterer, G., Mulherkar, N., Kuehne, A. I., Kranzusch, P. J., Griffin, A. M., Ruthel, G., Dal Cin, P., Dye, J. M., Whelan, S. P., Chandran, K., & Brummelkamp, T. R. (2011). Ebola virus entry requires the cholesterol transporter Niemann–Pick C1. Nature, 477(7364), 340–343. https://doi.org/10.1038/nature10348
2. Côté, M., Misasi, J., Ren, T., Bruchez, A., Lee, K., Filone, C. M., Hensley, L., Li, Q., Ory, D., Chandran, K., & Cunningham, J. (2011). Small molecule inhibitors reveal Niemann–Pick C1 is essential for Ebola virus infection. Nature, 477(7364), 344–348. https://doi.org/10.1038/nature10380
3. Wang, H., Shi, Y., Song, J., Qi, J., Lu, G., Yan, J., & Gao, G. F. (2016). Ebola viral glycoprotein bound to its endosomal receptor Niemann-Pick C1. Cell, 164(1–2), 258–268. https://doi.org/10.1016/j.cell.2015.12.044
4. Gong, X., Qian, H., Zhou, X., Wu, J., Wan, T., Cao, P., Huang, W., Zhao, X., Wang, X., Wang, P., Shi, Y., Gao, G. F., Zhou, Q., & Yan, N. (2016). Structural insights into the Niemann-Pick C1 (NPC1)-mediated cholesterol transfer. Cell, 165(6), 1467–1478. https://doi.org/10.1016/j.cell.2016.05.022